Hematological Malignancies In the News
City of Hope's Linda Malkas, Ph.D., never envisioned a life in cancer research for herself. She wanted to be an astronaut, but after attending engineering school, she abandoned her interest in going into space.
These three City of Hope physicians have dramatically different backgrounds, but they share a devotion to helping people and saving lives and now they share in the generosity of longtime City of Hope philanthropists Norman and Melinda Payson. Vijay Trisal, M.D., Jeffrey Weitzel, M.D., and John Chan, M.D., were recent invested through gifts made from the Payson family.
The Dr. Norman and Melinda Payson Professorships recognize City of Hope clinicians and researchers who have contributed greatly to biomedical research.
After many complications, City of Hope lymphoma patient Lucy found renewed hope after an immunotherapy clinical trial.
City of Hope’s CAR T research and treatment team is now an official member of the Parker Institute for Cancer Immunotherapy.
City of Hope’s John Zaia, M.D., will lead the development of the phase 1 clinical trial for glioblastoma patients, which would genetically alter blood stem cells to better tolerate chemotherapy.
Steven T. Rosen, M.D., just marked his fourth year at City of Hope as provost and chief scientific officer. On the occasion of his first four years at City of Hope and the recent five-year renewal of a National Cancer Institute grant, we sat down with Rosen to reflect on his time at City of Hope.
Joseph Alvarnas, M.D. describes himself as a storyteller, and for the City of Hope hematologist/oncologist, stories play a key role in how he sees the medical profession, his role in it, and even why he became a physician in the first place.
FDA approves tisagenlecleucel (commercial name Kymriah) CAR T cell therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Cheryl Wiers knew her cancer diagnosis happened for a reason, and for her, that reason could be her participation in a clinical trial using what is arguably the most promising cancer treatment — CAR T cell therapy.
CAR T Cells Save Chuck Fata's Life
City of Hope’s annual Kids 4 Hope program, in partnership with Albertsons Companies Foundation, Vons Foundation and Pavilions Foundation, has raised over $1 million to support research and treatment for pediatric cancers.
City of Hope physicians have successfully treated blood cancers with chimeric antigen receptor (CAR) T cell therapy, and they are working to expand that therapy to patients with prostate cancer and other solid tumors.
City of Hope today announced that it is a certified treatment center to administer tisagenlecleucel (commercial name Kymriah) chimeric antigen receptor (CAR) T cell therapy – the first CAR T cell therapy approved by the U.S. Food and Drug Administration (FDA) – to patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
City of Hope recently announced that it is a certified treatment center to administer tisagenlecleucel CAR T cell therapy – the first CAR T cell therapy approved by the U.S. Food and Drug Administration – to patients.
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will highlight a variety of basic research and population studies at the annual meeting of the American Association for Cancer Research (AACR) in Chicago’s McCormick Place April 14 to 18.
Reflections on Reuniting, One Year Later
A mother fights despair after a myeloma diagnosis
Often unrecognized are the countless folks who work in the spaces between the lab and the clinic — people responsible for doing everything from manufacturing CAR T cells to gaining federal approval for new trials.
Thanks to a $5.74 million award from the California Institute for Regenerative Medicine, City of Hope’s Joseph Rosenthal, M.D., and his team can advance their research into finding a cure for sickle cell disease.
In a new paper published in the journal Cell, a team of researchers led by City of Hope’s Markus Müschen, M.D., Ph.D., and Gang Xiao, Ph.D., reports on the discovery of a new therapeutic target for these B cell malignancies.
City of Hope researchers may have discovered a more effective treatment for patients with chronic myelogenous leukemia (CML) according to a study published today in Nature Medicine.
Thanks to research being done by City of Hope's Markus Müschen, M.D., Ph.D., lymphoma patients may soon receive treatments that leverage quality control mechanisms that our own immune systems utilize to fight harmful antibodies.
City of Hope scientists and doctors may have discovered a more effective treatment for patients with chronic myelogenous leukemia (CML) using a drug that was developed at the institution to eradicate CML stem cells, according to a study published today in Nature Medicine.
Acute myeloid leukemia, or AML, is one of the most common and fatal forms of blood-related cancers. Jianjun Chen, Ph.D., a new faculty member at City of Hope, dedicates much of his research program to learning more about the disease.